COVID-19aren aurkako txertoak: berrikuspenen arteko aldeak

| adenovirus[[adenobirus]] errekonbinatzailea 5 bektorea tipoa || II Faseko dosifikazio eta albo-ondorioetarako entsegu interbentzionista (500) || {{banderaikur|Txina}} [[Wuhan]], [[Txina]] || 2020ko martxotik 2020ko abendura || <ref>Clinical trial number [https://www.clinicaltrials.gov/show/NCT04341389 NCT04341389] for "A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)" at ClinicalTrials.gov</ref>

| adenovirusadenobirus errekonbinatzailea 5 bektorea tipoa || I Fasea (108) || {{banderaikur|Txina}} [[Wuhan]], [[Txina]] || 2020 martxotik 2020ko abendura || <ref>Clinical trial number [https://www.clinicaltrials.gov/ct2/show/NCT04313127 NCT04313127] for "A Phase I Clinical Trial in 18-60 Adults" at ClinicalTrials.gov</ref>

| adenovirusadenobirus bektorea || I-II Fasea, ausazkoa, plazeboz kontrolatua, leku anitzak (510) || {{banderaikur|Erresuma Batua}} [[Ingalaterra]], [[Erresuma Batua]] || 2020ko apiriletik 2021eko maiatzera || <ref>Clinical trial number [https://www.clinicaltrials.gov/ct2/show/NCT04324606 NCT04324606] for "A Study of a Candidate COVID-19 Vaccine (COV001)" at ClinicalTrials.gov</ref>

| [[ARN]] mezularidun nanopartikula lipidikoen hedapena || I Fasea (45) || {{banderaikur|AEB}} [[Estatu Batuak]] || 2020ko martxotik 2012eko udaberri-udara || <ref>[https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins NIH clinical trial of investigational vaccine for COVID-19 begins.] Publicado el 16 de marzo de 2020ko martxoaren 16an argitaratua.</ref><ref>Clinical trial number [https://www.clinicaltrials.gov/ct2/show/NCT04283461 NCT04283461] for "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection" at ClinicalTrials.gov</ref>